
Every breath carries information.
We turn it into action.
Starting with lung cancer, we’re building a new standard for respiratory diagnostics.
Lung cancer is the leading cause of cancer-related deaths worldwide.
Current tools are failing patients.
OUR TECHNOLOGY
Using our proprietary device and lab tests to improve diagnostic accuracy and speed.
Like the blood, the breath has its own biomarkers that can be used to indicate signs of disease. We are leading in the discovery of these biomarkers and bringing breath diagnostics into regular clinical practice.
Our proprietary device has already been tested with mesothelioma patients and was shown to be 60x more effective than other devices at collecting molecular data from the lungs.
HOW IT WORKS
01
02
03
BENEFITS
Our technology provides better insights without radiation or needles.
✓ Enables molecular profiling from the breath, equivalent to that of tissue biopsies.
✓ Detects lung cancer and respiratory disease early, without needles, scans, or radiation (there is 1 radiation induced death for every 13 lives saved from lung cancer screening!)
✓ Can be delivered in primary care settings, improving access and uptake.
OUR FOUNDING TEAM

Alison Quinn
Commercial leader with extensive experience in healthcare product development, go-to-market strategy, and commercial partnerships.

Dr Theo Issitt
A breath analysis expert with 15+ publications in breath and cell biology and years of experience developing and testing breath collection platforms.
With support from

Support non-invasive solutions for earlier detection, diagnoses, and precision medicine.
Created by Respiro Diagnostics
Contact us at Alison@RespiroDiagnostics.com